Sandostatin — CareFirst (Caremark)

Initial criteria

• Management of GI symptoms (e.g., nausea, pain, vomiting) of inoperable bowel obstruction in members with cancer

Reauthorization criteria

• Member is experiencing clinical benefit as evidenced by improvement or stabilization in clinical signs and symptoms since initiation of therapy

Approval duration

12 months